Thomas Fleming
- Oncology top 0.2%
- Clinical Biochemistry top 0.1%
- Advanced Glycation End Products research 59
- Cancer Research top 0.5%
-
- Biochemical effects in animals 14
- Pain Mechanisms and Treatments 13
- Diet and metabolism studies 6
-
- Natural Antidiabetic Agents Studies 9
- Diabetes, Cardiovascular Risks, and Lipoproteins 9
-
- Alcohol Consumption and Health Effects 7
-
- Neuroinflammation and Neurodegeneration Mechanisms 6
- Co-authors
- W. EiermannVirginia PatonDennis J. SlamonAlex BajamondeLarry NortonJosé BaselgaMark D. PegramSteven Shak
- Journals
- Experimental and Clinical Endocrinology & Diabetes (8 papers)Journal of Biological Chemistry (5 papers)Redox Biology (5 papers)
- Partner nations
- GermanyUnited StatesUnited Kingdom
In The Last Decade
Thomas Fleming
108 papers receiving 11.6k citations
Hit Papers
Peers
Comparison fields: 5 of 138
- Oncology 6.5k
- Clinical Biochemistry 1.2k
- Cancer Research 2.1k
- Radiology, Nuclear Medicine and Imaging 3.0k
- Pulmonary and Respiratory Medicine 1.7k
Countries citing papers authored by Thomas Fleming
This map shows the geographic impact of Thomas Fleming's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Fleming with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Fleming more than expected).
Fields of papers citing papers by Thomas Fleming
This network shows the impact of papers produced by Thomas Fleming. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Fleming. The network helps show where Thomas Fleming may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Thomas Fleming, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 3 | |
| 2 | 2024 | 5 | |
| 3 | 2023 | 10 | |
| 4 | 2021 | 42 | |
| 5 | 2020 | 4 | |
| 6 | 2020 | 14 | |
| 7 | 2019 | 11 | |
| 8 | 2018 | 55 | |
| 9 | 2018 | 127 | |
| 10 | 2018 | 28 | |
| 11 | 2017 | 14 | |
| 12 | 2016 | 17 | |
| 13 | 2016 | 8 | |
| 14 | 2015 | 7 | |
| 15 | 2015 | 7 | |
| 16 | 2014 | 33 | |
| 17 | 2014 | 21 | |
| 18 | 2013 | 16 | |
| 19 | 2012 | 160 | |
| 20 | 2010 | 97 |
About Thomas Fleming
Thomas Fleming is a scholar working on Clinical Biochemistry, Aging and Endocrinology, Diabetes and Metabolism, having authored 110 papers that have together received 11.9k indexed citations. Recurring topics across this work include Advanced Glycation End Products research (59 papers), Biochemical effects in animals (14 papers), Pain Mechanisms and Treatments (13 papers), Natural Antidiabetic Agents Studies (9 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (9 papers), Alcohol Consumption and Health Effects (7 papers), Diet and metabolism studies (6 papers) and Neuroinflammation and Neurodegeneration Mechanisms (6 papers). The work is most often cited by research in Oncology (6.5k citations), Clinical Biochemistry (1.2k citations) and Cancer Research (2.1k citations). Thomas Fleming has collaborated with scholars based in Germany, United States and United Kingdom. Frequent co-authors include W. Eiermann, Virginia Paton, Dennis J. Slamon, Alex Bajamonde, Larry Norton, José Baselga, Mark D. Pegram, Steven Shak, Brian Leyland‐Jones and Janet Wolter. Their work appears in journals such as Experimental and Clinical Endocrinology & Diabetes, Journal of Biological Chemistry, Redox Biology, Diabetologia and Acta Diabetologica.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.